Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia
We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may...
Gespeichert in:
| Veröffentlicht in: | Schizophrenia research 2001-10, Vol.52 (1), p.115-120 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 120 |
|---|---|
| container_issue | 1 |
| container_start_page | 115 |
| container_title | Schizophrenia research |
| container_volume | 52 |
| creator | Laakso, Aki Bergman, Jörgen Haaparanta, Merja Vilkman, Harry Solin, Olof Syvälahti, Erkka Hietala, Jarmo |
| description | We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may vary depending on the illness phase, we studied DAT density in eight stable, medicated chronic schizophrenic patients and eight matched controls using positron emission tomography and [
18F]CFT, a marker of dopamine nerve terminals. [
18F]CFT binding potentials were significantly lower in chronic schizophrenic patients than in controls, both in the caudate and the putamen (−9 to −16%). Together with the finding of unchanged average striatal DAT levels in first-episode patients and relative insensitivity of striatal [
18F]CFT binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of DAT in a subset of chronic schizophrenic patients. |
| doi_str_mv | 10.1016/S0920-9964(00)00095-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72188814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920996400000955</els_id><sourcerecordid>72188814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-921680e99f501087d1e66879a5d00d5570bb9ca929d3320815e81c1208bac2a53</originalsourceid><addsrcrecordid>eNqF0E1v1DAQgGELFdFt4ScU5VJUDoGZJE7sU1W15UNaqUjA2XLsSdcoawc7uxL99SS7ET1yGh8ee6yXsQuEDwhYf_wOsoBcyrq6AngPAJLn_AVbIW_KvOAgT9jqHzllZyn9mhByaF6xU0QueSnFin27IxNJJ7JZGqPTo-4zGwa9dZ6yMWqfhhBHilnrvHX-MXM-27t9mKfZxOCdyZLZuKcwbCJ5p1-zl53uE71Z5jn7-en-x-2XfP3w-evtzTo3FW_GXBZYCyApOw4IorFIdS0aqbkFsJw30LbSaFlIW5YFCOQk0OB0arUpNC_P2bvju0MMv3eURrV1yVDfa09hl1RToBACqwnyIzQxpBSpU0N0Wx3_KAQ1p1SHlGrupADUIaWaF7xdFuzaLdnnW0u7CVwuQCej-26KZVx6dhXUBcpmctdHR1OOvaOoknHkDVkXyYzKBvefr_wFO82Pzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72188814</pqid></control><display><type>article</type><title>Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Laakso, Aki ; Bergman, Jörgen ; Haaparanta, Merja ; Vilkman, Harry ; Solin, Olof ; Syvälahti, Erkka ; Hietala, Jarmo</creator><creatorcontrib>Laakso, Aki ; Bergman, Jörgen ; Haaparanta, Merja ; Vilkman, Harry ; Solin, Olof ; Syvälahti, Erkka ; Hietala, Jarmo</creatorcontrib><description>We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may vary depending on the illness phase, we studied DAT density in eight stable, medicated chronic schizophrenic patients and eight matched controls using positron emission tomography and [
18F]CFT, a marker of dopamine nerve terminals. [
18F]CFT binding potentials were significantly lower in chronic schizophrenic patients than in controls, both in the caudate and the putamen (−9 to −16%). Together with the finding of unchanged average striatal DAT levels in first-episode patients and relative insensitivity of striatal [
18F]CFT binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of DAT in a subset of chronic schizophrenic patients.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/S0920-9964(00)00095-5</identifier><identifier>PMID: 11595398</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Biological and medical sciences ; Brain Mapping ; CFT ; Chronic Disease ; Cocaine - analogs & derivatives ; Cocaine - pharmacokinetics ; Corpus Striatum - diagnostic imaging ; Dominance, Cerebral - physiology ; Dopamine Plasma Membrane Transport Proteins ; Dopamine transporter ; Dopamine Uptake Inhibitors - pharmacokinetics ; Female ; Humans ; Male ; Medical sciences ; Membrane Glycoproteins ; Membrane Transport Proteins - metabolism ; Nerve Tissue Proteins ; Positron emission tomography ; Psychiatric Status Rating Scales ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Radioligand Assay ; Schizophrenia ; Schizophrenia - diagnostic imaging ; Schizophrenia - physiopathology ; Tomography, Emission-Computed ; WIN 35,428</subject><ispartof>Schizophrenia research, 2001-10, Vol.52 (1), p.115-120</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-921680e99f501087d1e66879a5d00d5570bb9ca929d3320815e81c1208bac2a53</citedby><cites>FETCH-LOGICAL-c457t-921680e99f501087d1e66879a5d00d5570bb9ca929d3320815e81c1208bac2a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0920996400000955$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14062197$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11595398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laakso, Aki</creatorcontrib><creatorcontrib>Bergman, Jörgen</creatorcontrib><creatorcontrib>Haaparanta, Merja</creatorcontrib><creatorcontrib>Vilkman, Harry</creatorcontrib><creatorcontrib>Solin, Olof</creatorcontrib><creatorcontrib>Syvälahti, Erkka</creatorcontrib><creatorcontrib>Hietala, Jarmo</creatorcontrib><title>Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may vary depending on the illness phase, we studied DAT density in eight stable, medicated chronic schizophrenic patients and eight matched controls using positron emission tomography and [
18F]CFT, a marker of dopamine nerve terminals. [
18F]CFT binding potentials were significantly lower in chronic schizophrenic patients than in controls, both in the caudate and the putamen (−9 to −16%). Together with the finding of unchanged average striatal DAT levels in first-episode patients and relative insensitivity of striatal [
18F]CFT binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of DAT in a subset of chronic schizophrenic patients.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Biological and medical sciences</subject><subject>Brain Mapping</subject><subject>CFT</subject><subject>Chronic Disease</subject><subject>Cocaine - analogs & derivatives</subject><subject>Cocaine - pharmacokinetics</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Dominance, Cerebral - physiology</subject><subject>Dopamine Plasma Membrane Transport Proteins</subject><subject>Dopamine transporter</subject><subject>Dopamine Uptake Inhibitors - pharmacokinetics</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins</subject><subject>Membrane Transport Proteins - metabolism</subject><subject>Nerve Tissue Proteins</subject><subject>Positron emission tomography</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Radioligand Assay</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnostic imaging</subject><subject>Schizophrenia - physiopathology</subject><subject>Tomography, Emission-Computed</subject><subject>WIN 35,428</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1v1DAQgGELFdFt4ScU5VJUDoGZJE7sU1W15UNaqUjA2XLsSdcoawc7uxL99SS7ET1yGh8ee6yXsQuEDwhYf_wOsoBcyrq6AngPAJLn_AVbIW_KvOAgT9jqHzllZyn9mhByaF6xU0QueSnFin27IxNJJ7JZGqPTo-4zGwa9dZ6yMWqfhhBHilnrvHX-MXM-27t9mKfZxOCdyZLZuKcwbCJ5p1-zl53uE71Z5jn7-en-x-2XfP3w-evtzTo3FW_GXBZYCyApOw4IorFIdS0aqbkFsJw30LbSaFlIW5YFCOQk0OB0arUpNC_P2bvju0MMv3eURrV1yVDfa09hl1RToBACqwnyIzQxpBSpU0N0Wx3_KAQ1p1SHlGrupADUIaWaF7xdFuzaLdnnW0u7CVwuQCej-26KZVx6dhXUBcpmctdHR1OOvaOoknHkDVkXyYzKBvefr_wFO82Pzw</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Laakso, Aki</creator><creator>Bergman, Jörgen</creator><creator>Haaparanta, Merja</creator><creator>Vilkman, Harry</creator><creator>Solin, Olof</creator><creator>Syvälahti, Erkka</creator><creator>Hietala, Jarmo</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia</title><author>Laakso, Aki ; Bergman, Jörgen ; Haaparanta, Merja ; Vilkman, Harry ; Solin, Olof ; Syvälahti, Erkka ; Hietala, Jarmo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-921680e99f501087d1e66879a5d00d5570bb9ca929d3320815e81c1208bac2a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Biological and medical sciences</topic><topic>Brain Mapping</topic><topic>CFT</topic><topic>Chronic Disease</topic><topic>Cocaine - analogs & derivatives</topic><topic>Cocaine - pharmacokinetics</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Dominance, Cerebral - physiology</topic><topic>Dopamine Plasma Membrane Transport Proteins</topic><topic>Dopamine transporter</topic><topic>Dopamine Uptake Inhibitors - pharmacokinetics</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins</topic><topic>Membrane Transport Proteins - metabolism</topic><topic>Nerve Tissue Proteins</topic><topic>Positron emission tomography</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Radioligand Assay</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnostic imaging</topic><topic>Schizophrenia - physiopathology</topic><topic>Tomography, Emission-Computed</topic><topic>WIN 35,428</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laakso, Aki</creatorcontrib><creatorcontrib>Bergman, Jörgen</creatorcontrib><creatorcontrib>Haaparanta, Merja</creatorcontrib><creatorcontrib>Vilkman, Harry</creatorcontrib><creatorcontrib>Solin, Olof</creatorcontrib><creatorcontrib>Syvälahti, Erkka</creatorcontrib><creatorcontrib>Hietala, Jarmo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laakso, Aki</au><au>Bergman, Jörgen</au><au>Haaparanta, Merja</au><au>Vilkman, Harry</au><au>Solin, Olof</au><au>Syvälahti, Erkka</au><au>Hietala, Jarmo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>52</volume><issue>1</issue><spage>115</spage><epage>120</epage><pages>115-120</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may vary depending on the illness phase, we studied DAT density in eight stable, medicated chronic schizophrenic patients and eight matched controls using positron emission tomography and [
18F]CFT, a marker of dopamine nerve terminals. [
18F]CFT binding potentials were significantly lower in chronic schizophrenic patients than in controls, both in the caudate and the putamen (−9 to −16%). Together with the finding of unchanged average striatal DAT levels in first-episode patients and relative insensitivity of striatal [
18F]CFT binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of DAT in a subset of chronic schizophrenic patients.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11595398</pmid><doi>10.1016/S0920-9964(00)00095-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-9964 |
| ispartof | Schizophrenia research, 2001-10, Vol.52 (1), p.115-120 |
| issn | 0920-9964 1573-2509 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72188814 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Adult and adolescent clinical studies Biological and medical sciences Brain Mapping CFT Chronic Disease Cocaine - analogs & derivatives Cocaine - pharmacokinetics Corpus Striatum - diagnostic imaging Dominance, Cerebral - physiology Dopamine Plasma Membrane Transport Proteins Dopamine transporter Dopamine Uptake Inhibitors - pharmacokinetics Female Humans Male Medical sciences Membrane Glycoproteins Membrane Transport Proteins - metabolism Nerve Tissue Proteins Positron emission tomography Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Radioligand Assay Schizophrenia Schizophrenia - diagnostic imaging Schizophrenia - physiopathology Tomography, Emission-Computed WIN 35,428 |
| title | Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A02%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20striatal%20dopamine%20transporter%20binding%20in%20vivo%20in%20chronic%20schizophrenia&rft.jtitle=Schizophrenia%20research&rft.au=Laakso,%20Aki&rft.date=2001-10-01&rft.volume=52&rft.issue=1&rft.spage=115&rft.epage=120&rft.pages=115-120&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/S0920-9964(00)00095-5&rft_dat=%3Cproquest_cross%3E72188814%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72188814&rft_id=info:pmid/11595398&rft_els_id=S0920996400000955&rfr_iscdi=true |